A flow-based synthesis of imatinib: the API of Gleevec.
Hopkin
Mark D
MD
Innovative Technology Centre, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.
Baxendale
Ian R
IR
Ley
Steven V
SV
D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D001549:Benzamides; D004123:Dimethylamines / Q000737:chemistry; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D000077489:Piperazine; D010879:Piperazines / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D004123:Dimethylamines; D010879:Piperazines; D011743:Pyrimidines; D000077489:Piperazine; D000068877:Imatinib Mesylate; C034516:dimethylamine